Related Experiment Video

Updated: Mar 28, 2026

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

8.3K

Increased Protease-Activated Receptor-2 (PAR-2) Expression on CD14++CD16+ Peripheral Blood Monocytes of Patients with

Nami Shrestha Palikhe1, Drew Nahirney1, Cheryl Laratta1

  • 1Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Plos One
|December 15, 2015
PubMed
Abstract

Insights

Protease-Activated Receptor-2 (PAR-2) is elevated on intermediate monocytes in severe asthma patients, potentially serving as a biomarker for disease severity and exacerbations.

Area of Science:

  • Immunology
  • Respiratory Medicine
  • Cell Biology

Background:

  • Protease-Activated Receptor-2 (PAR-2) is a G protein-coupled receptor involved in inflammation.
  • PAR-2 activation in airways contributes to allergic airway inflammation.
  • While PAR-2 is upregulated in asthma epithelium, its role on inflammatory cells is unstudied.

Purpose of the Study:

  • To investigate PAR-2 expression on blood inflammatory cells in patients with mild/moderate and severe asthma.
  • To determine if PAR-2 expression correlates with asthma severity or exacerbation history.

Main Methods:

  • Recruited 12 severe and 24 mild/moderate asthmatics.
  • Collected demographic, medication, and asthma severity data.
  • Analyzed PAR-2 expression on blood inflammatory cells using flow cytometry.

Main Results:

  • Severe asthmatics showed higher PAR-2 expression on intermediate monocytes (CD14++CD16+).
  • A higher percentage of intermediate monocytes expressing PAR-2 distinguished severe from mild/moderate asthma.
  • Increased PAR-2+ intermediate monocytes correlated with a history of asthma exacerbations.

Conclusions:

  • PAR-2 expression on peripheral blood intermediate monocytes is increased in severe asthma.
  • PAR-2 on these monocytes may serve as a biomarker for asthma severity.
  • PAR-2-mediated monocyte activation could contribute to severe asthma pathogenesis.

More Related Videos

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

44.3K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

23.6K

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K